Molecular, Genetic and Regenerative Ophthalmology
- Genetic eye diseases & inherited retinal dystrophies
- Genotype–phenotype correlations & diagnostic pipelines
- Next-generation sequencing & variant interpretation in ophthalmology
- Gene therapy & CRISPR-based editing for retinal disorders
- RNA therapeutics & antisense oligonucleotides for vision restoration
- Stem-cell–based regeneration for corneal & retinal repair
- Organoids, 3D bioprinting & tissue-engineered ocular models
- Mitochondrial dysfunction, oxidative stress & aging in the eye
- Epigenetic regulation of ocular development & degeneration
- Nanomedicine & biomaterials for ocular gene/drug delivery
From single-nucleotide variants to bioengineered tissues, this session traces how molecular mechanisms become measurable phenotypes and ultimately targeted interventions for vision restoration. We connect genotype–phenotype mapping with functional readouts—transcriptomics, proteomics, metabolomics, epigenomics—to explain why patients with similar clinical pictures may respond differently to the same therapy. You’ll see how CRISPR platforms, base and prime editing, antisense oligonucleotides, and RNA therapeutics move from bench protocols to validated clinical workflows, and how manufacturing, analytics, and long-term monitoring are designed for safety and durability. We also cover cell sources and differentiation roadmaps for corneal, limbal, and retinal lineages; tissue scaffolds and hydrogels that preserve architecture; and organoid and organ-on-chip systems that model disease with human fidelity. By aligning discovery biology with meaningful clinical endpoints, Molecular, Genetic & Regenerative Ophthalmology shows how to de-risk early programs and accelerate first-in-human milestones. If you’re scanning Vision Conference to find where lab data meets clinical relevance, this track is built for you. We emphasize pragmatic topics—assay selection, potency criteria, vector choice, biodistribution, immunogenicity, and real-world follow-up—so teams can move beyond proof-of-concept toward scalable access. Along the way, we highlight regulatory and ethical considerations for consent, return of results, and equitable enrollment, while showcasing platforms that compress the cycle from discovery to patient benefit. Whether your focus is variant interpretation, vector engineering, cell therapy manufacturing, or translational biomarkers, this page outlines the playbook to turn mechanism into medicine, with special attention to durability, retreatment strategies, and combination approaches. For those new to regenerative strategies, start with stem-cell lineage decisions and scaffold design; for advanced teams, dive into potency assays, release specifications, and adaptive trial designs. End-to-end, you’ll learn how gene therapy and regenerative platforms can be integrated with imaging, electrophysiology, and functional measures to deliver precise, durable vision care.
Ready to Share Your Research?
Submit Your Abstract Here →Present your research under Molecular, Genetic and Regenerative Ophthalmology
Translational Pillars and Focus Areas
Variant Discovery and Interpretation
- Building curated panels and leveraging population databases for pathogenicity calls
- Establishing multidisciplinary boards to align molecular findings with clinical actionability
Therapeutic Nucleic Acids and Editing
- Choosing ASO, siRNA, or mRNA routes based on target biology and tissue access
- Designing CRISPR/editing strategies with off-target assessment and repair pathway control
Vectorology and Delivery to the Eye
- Selecting AAV/viral versus non-viral systems aligned to target cell types and payload size
- Optimizing subretinal, intravitreal, or suprachoroidal administration for exposure and safety
Cell Sources and Regenerative Platforms
- Differentiating iPSC-derived RPE/photoreceptors and limbal cells with stable phenotypes
- Using biomimetic scaffolds, hydrogels, and bioprinting to preserve tissue architecture
Organoids, Disease Models, and Potency
- Modeling inherited and acquired disease in human-relevant organoids and chips
- Defining potency assays and release criteria that predict clinical performance
Immunogenicity, Safety, and Durability
- Profiling innate/adaptive responses and mitigating inflammation and neutralizing antibodies
- Designing durability assessments and retreatment frameworks with clear stopping rules
From Bench Insight to Patient Impact
Biomarker Strategy
Link omics readouts and imaging with functional endpoints to enable earlier go/no-go decisions
Trial Design and Endpoints
Use adaptive designs, enrichment, and validated surrogates for efficient first-in-human studies
Manufacturing and Quality
Define GMP-ready workflows, sterility controls, and chain-of-identity/chain-of-custody systems
Regulatory and Ethics
Align with evolving guidance on editing, pediatric research, and return-of-results policies
Combination Approaches
Integrate editing or ASOs with neuroprotection, small molecules, or devices for durability
Access and Equity
Plan for affordability, newborn screening pilots, and diverse recruitment to avoid disparities
Real-World Evidence
Build registries and long-term follow-up to capture durability, safety signals, and QoL
Data & AI Enablement
Apply AI for variant calling, image quantification, and predictive dosing across cohorts
Related Sessions You May Like
Join the Global Ophthalmology Community
Connect with ophthalmologists, vision researchers, and eye-care specialists worldwide. Share your expertise and explore the latest advances in eye diseases, vision science, diagnostics, and innovative treatment technologies.
